Cleared Traditional

K233454 - ONLINE TDM Methotrexate (FDA 510(k) Clearance)

K233454 · Roche Diagnostics Operations · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2024
Decision
123d
Days
-
Risk

K233454 is an FDA 510(k) clearance for the ONLINE TDM Methotrexate. Classified as Enzyme Immunoassay, Methotrexate (product code LAO).

Submitted by Roche Diagnostics Operations (Indianapolis, US). The FDA issued a Cleared decision on February 20, 2024 after a review of 123 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Roche Diagnostics Operations devices

Submission Details

510(k) Number K233454 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 20, 2023
Decision Date February 20, 2024
Days to Decision 123 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
36d slower than avg
Panel avg: 87d · This submission: 123d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code LAO Enzyme Immunoassay, Methotrexate
Device Class -